Independent Research set a €52.50 ($61.05) price target on Bayer (FRA:BAYN) in a research note issued to investors on Friday, March 29th, Borsen Zeitung reports. The firm currently has a sell rating on the healthcare company’s stock.
Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Bayer in a research report on Thursday, November 29th. Sanford C. Bernstein set a €86.00 ($100.00) target price on shares of Bayer and gave the company a buy rating in a research report on Wednesday, March 20th. UBS Group set a €110.00 ($127.91) target price on shares of Bayer and gave the company a buy rating in a research report on Tuesday, January 8th. Nord/LB set a €72.00 ($83.72) target price on shares of Bayer and gave the company a neutral rating in a research report on Wednesday, February 27th. Finally, DZ Bank reaffirmed a buy rating on shares of Bayer in a research report on Tuesday, December 4th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of €81.80 ($95.12).
Shares of BAYN traded down €0.38 ($0.44) during midday trading on Friday, reaching €61.16 ($71.12). The stock had a trading volume of 4,465,525 shares. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: What is a Derivative?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.